British Columbia Investment Management Corp I Mab Transaction History

British Columbia Investment Management Corp

$16 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $131,493 - $293,037	-15,900 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$45.28 - $74.5 $108,672 - $178,800	2,400 Added 17.78%	15,900 $754,000
Q2 2021 Aug 09, 2021	BUY	$47.86 - $83.95 $646,110 - $1.13 Million	13,500 New	13,500 $1.13 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

15.5M

Call Options Held

56.4K

Put Options Held

5.8K

Hhlr Advisors, Ltd. Grand Cayman, E9

6.91M
Shares

$6.36 Million
0.2% of portfolio
Decheng Capital Management Iii (Cayman), LLC

4.17M
Shares

$3.83 Million
3.04% of portfolio
Boothbay Fund Management, LLC New York, NY

1.42M
Shares

$1.31 Million
0.05% of portfolio
Temasek Holdings (Private) LTD Singapore, U0

567K
Shares

$521,318
0.0% of portfolio
David A. Siegel Two Sigma Advisers, LP | New York, Ny

499K
Shares

$459,356
0.0% of portfolio

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $76.5M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of British Columbia Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on British Columbia Investment Management Corp with notifications on news.

Account